Strong Q1 For Chugai But Virus Uncertainties Loom
Chugai says coronavirus business impact has been minor so far but cautions this could change after a strong first quarter.
You may also be interested in...
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
Entrectinib becomes first tumor-agnostic drug to be launched in Japan, its second market globally after the US, but commercial prospects will be limited given the highly specific patient population.
In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.